Biosimilar Pipeline | Amgen Biosimilars
CLEAR

Inflammation

Hematology / Oncology

Our Pipeline

ABP 654 (Investigational biosimilar to STELARA® (ustekinumab))

ABP 654 is an investigational biosimilar to STELARA® (ustekinumab). It is a monoclonal antibody that inhibits

IL-12 and IL-23.

ABP 938 (Investigational biosimilar to EYLEA® (aflibercept))

ABP 938 is an investigational biosimilar to EYLEA® (aflibercept). It is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein.

ABP 959 (Investigational biosimilar to SOLIRIS® (eculizumab))

ABP 959 is an investigational biosimilar to SOLIRIS® (eculizumab). It is a monoclonal antibody that specifically binds to the complement protein C5.

STELARA is a trademark of Janssen Biotech, Inc.

EYLEA is a trademark of Regeneron Pharmaceuticals, Inc.

SOLIRIS is a trademark of Alexion Pharmaceuticals, Inc.

Next: FDA-Approved Products Next: clinical trials